Medtronic discovered novel SenSight™ Directional Lead System developed for Deep Brain Stimulation (DBS) therapy.
The SenSight™ system incorporates the benefits of directionality with the power of sensing and allowing physicians in delivering precise, patient-specific DBS therapy for the treatment of symptoms related with movement disorders such as dystonia, Parkinson's disease, essential tremor, and medically refractory epilepsy.
With the introduction of this new directional lead with a pulse generator capable of brain sensing, the patients are benefitted with both the technologies.
The DBS system is designed with a small pacemaker-like device which sends electrical signals through very thin wires targeting the symptoms of neurological disorders in brain.
SenSight, first directional, sensing-enabled lead which is 1 million times smaller than DBS stimulation pulses is designed to boost the detection of local field potentials (LFPs), brain signals correlating with the severity of Parkinson's disease symptoms.
U.S. Food and Drug Administration (FDA)grants approval for SenSight™ Directional Lead System designed forDeep Brain Stimulation (DBS) therapy.
